UK-based GW Pharmaceuticals announced on Monday, positive results from a late stage study of its cannabidiol drug Epidiolex for the treatment of Dravet syndrome, a rare and debilitating type of epilepsy in children.
According to the company’s press release, “In this study Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo…” An article published on Monday in theCannabist provides extensive coverage and good insights into the significance of this announcement.
Media outlets have also reported that GW Pharmaceuticals stock skyrocketed following the announcement. See links below.
http://fortune.com/2016/03/14/marijuana-insys-zynerba-gw/
